NEJM: Obinutuzumab in Active Systemic Lupus Erythematosus A phase 3 trial of obinutuzumab, an anti-CD20 monoclonal antibody, showed potent B-cell depletion and clinical efficacy active systemic lupus erythematosus without evidence of nephritis. https://t.co/b5qHBotxbI https://t.co/dqzZodOokq

Data from the KEEPsAKE 1 trial in bio-naive patients with PsA Dr. Wells and Dr. Singla share 5-year safety and efficacy data of an IL–23 inhibitor and their thoughts on using it to manage PsA. Sponsored by AbbVie Medical Affairs + Health Impact.  https://t.co/xoPdYAof7m https://t.co/ycqMod2qLN

Prebiotic fibre improves knee OA. Study of 117 older adults w/ KOA Rx w/ 6wks of inulin (fibre) or Physiotherapy exercise (PSE) or both vs PBO. Both Inulin & PSE signif improved pain & PSE vs PBO ( −1.11 to -2.5; p <0.045); inulin also improved pain sensitivity & grip strength https://t.co/Efic4mru1i

Long-Term Hydroxychloroquine Retinopathy Risk About one in 18 patients taking hydroxychloroquine (HCQ) for 15 years develop retinal damage, a new meta-analysis indicated. https://t.co/Gp6o0FfEYA https://t.co/TjLNXl229v

AI model was superior in diagnosing Acromegaly from dorsal hand photographs - w. sensitivity 0.89, specificity 0.91, PPV 0.88, NPV 0.93, F1-score of 0.89, AUC 0.96, outperforming specialists, Study of 716 pts (317 acromegaly; 399 controls) & 11480 images, from 15 Japanese https://t.co/8RM4wf8vGi

Basic, full-read overview of "JAK inhibitors: risks and safety principles" from the Pharmaceutical Journal. Addresses MOA, indications, warnings, monitoring, adverse effects, interactions, Serious AEs, vaccination and best practices. https://t.co/qrqeu1CzRg https://t.co/7qIszLwUrf

TYK2 Inhibitor Deucravacitinib FDA Approved for Psoriatic Arthritis On Friday, March 6th, the FDA approved deucravacitinib (Sotyktu) for the treatment of adults with active PsA based on the results of the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials. https://t.co/a6rmortnoS

https://t.co/4UQlqwujiR 2026 — On Demand Catch the sessions everyone in rheumatology is talking about: • RA advances • Psoriatic arthritis decisions • Spondyloarthritis updates • Autoimmune disease highlights • Vasculitis insights Full recordings + slides available now. https://t.co/wGrptPBYNu

Swiss study of 1st TNFi efficacy in 3324 axial spondy (axSpA) (≤1 yr=very early Dz,441; 1-2 yrs =early axSpA, 218; >2 yrs=establi axSpA, 2575). After adjusting for age/sex, B27, etc, no signif. difference seen when TNFi started regarding later outcomes: TNFi retention, or ASDAS https://t.co/1EaP8UOsVt

Korean National Insurance claims study (2010–2023) of treatment persistence of IL-17i vs TNFi (IL-17i: 375; TNFi: 1285) in 1660 axSpA pts found equal Tx durations. However, primary nonresponse D/C was significantly higher w/ TNFi vs IL-17i (adj HR 1.54 to 2.11) https://t.co/2CF4OCPT6z

UBER Rheumatology Ride (3.6.2026) Dr. Jack Cush reviews the news and journal reports from this week on RheumNow. https://t.co/iDNCJMLe4S https://t.co/amsEJ8Q5MI